Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersAaron M. Goodman, Razelle Kurzrock, Shumei Kato et al.|Molecular Cancer Therapeutics|2017Cited by 2.4k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Vamsidhar Velcheti et al.|New England Journal of Medicine|2020Cited by 835
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based ImmunotherapyYulian Khagi, Razelle Kurzrock, Aaron M. Goodman et al.|Clinical Cancer Research|2017Cited by 202
Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung AdenocarcinomaMaria Schwaederlé, Razelle Kurzrock, Sandip Pravin Patel et al.|Clinical Cancer Research|2017Cited by 147
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D. Engstrom, James G. Christensen, Ruth Aranda et al.|Clinical Cancer Research|2017Cited by 147